Results 51 to 60 of about 7,224 (167)

Validation of a Point‐Of‐Care Ultrasound for Hepatitis Among Front‐Line Healthcare Workers Managing Chronic Hepatitis B Virus Infection in Zambia

Journal of Viral Hepatitis, Volume 33, Issue 9, September 2026.
ABSTRACT To close gaps in implementing care of people with hepatitis B virus (HBV) infection in resource‐limited settings, we evaluated the accuracy of a novel liver point‐of‐care ultrasound (POCUS) protocol for hepatitis (PUSH) among front‐line non‐radiology healthcare workers in Zambia. At University Teaching Hospital in Lusaka, Zambia, from March to
Costanza Bertoni, Annie Kanunga, Edford Sinkala, Enock Syabbalo, Helen Chitundu, Alick Chikwezi, Carolyn Chibundi, Guy K. Muula, Samuel Bosomprah, Nicolò Capra, Riccardo Lolatto, Giulia Morsica, Antonella Castagna, Claudia Wallrauch, Tom Heller, Michael J. Vinikoor   +15 more
wiley   +1 more source

A United States HIV provider survey of antiretroviral therapy management in people living with HIV with co-occurring conditions

AIDS Research and Therapy
Introduction Simplified HIV treatment guidelines favor integrase strand transfer inhibitors (INSTIs). However, non-infectious comorbidities and co-occurring conditions (i.e.
Sonya Krishnan, Marina B. Martinez Rivera, Christopher K. Lippincott, Maunank Shah   +3 more
doaj   +1 more source

PrEP at the site of action in cisgender and transgender women: A pharmacology study of blood and rectal CD4+ lymphocytes

British Journal of Clinical Pharmacology, Volume 92, Issue 8, Page 2949-2959, August 2026.
Background Female sex hormones used in feminizing hormone therapy (FHT) may influence activation and persistence of HIV pre‐exposure prophylaxis (PrEP) medications. The clinical relevance of this interaction remains unclear, particularly for transgender and cisgender women (TGW and CGW).
Elizabeth Hastie, Megha Srivasta, Edward R. Cachay, Leah Burke, Sara Gianella, Stephen Rawlings, Frank Z. Stanczyk, Craig Sykes, Angela D. M. Kashuba, Jill Blumenthal, Mackenzie L. Cottrell   +10 more
wiley   +1 more source

Health care providers' decision-making and early adoption of tenofovir alafenamide for HIV preexposure prophylaxis: An inductive qualitative study.

PLoS ONE
BackgroundOver the past several years, there have been several changes affecting the available options for oral HIV preexposure prophylaxis, including approvals for tenofovir alafenamide with emtricitabine in 2019 and a generic formulation of tenofovir ...
Elisabeth Merchant, Patricia Solleveld, Kevin Gibas, Douglas Krakower   +3 more
doaj   +1 more source

Bard1‐Mediated Regulation of Hnrnpa2b1 Ubiquitination and Protein Stability Contributes to Neuronal Ferroptosis and Cognitive Dysfunction Following Ischemic Stroke

CNS Neuroscience &Therapeutics, Volume 32, Issue 8, August 2026.
Bard1‐mediated ubiquitination of Hnrnpa2b1 in mice with PSCI destabilizes Sptbn2, which prevents the membrane translocation of Slc7a11 and reduces cystine uptake. This disruption of antioxidant defense triggers ferroptosis in hippocampal neurons, highlighting a novel molecular pathway linking post‐stroke cognitive impairment to ferroptosis of ...
Tuming Li, Tianyi Rong, Zuoting Shen, Zhenyu Wei, Deyan Chen, Ping Zhong, Li Cao   +6 more
wiley   +1 more source

Tenofovir Alafenamide [PDF]

Reactions Weekly, 2020
  +4 more sources

Vector‐based comparison as a novel framework for assessing multi‐endpoint clinical trials: Applications to actual data

Clinical and Translational Discovery, Volume 6, Issue 4, August 2026.
Multi‐endpoint clinical trials face long‐standing statistical challenges. Vector‐based comparison (VBC) decomposes endpoints into orthogonal components. Applied to five clinical trials, it reduced confidence‐interval widths by about 50%, indicating higher statistical power, without altering the clinical meaning of endpoints.
Maria Kokkali, Vangelis D. Karalis
wiley   +1 more source

Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles [PDF]

Clinical and Molecular Hepatology, 2022
Hung-Yao Lin, Tai-Chung Tseng
doaj   +1 more source

Fanconi Syndrome Due to Tenofovir Disoproxil Fumarate in a Patient with Chronic Hepatitis B Induced Cirrhosis: A Case Report

Case Reports in Clinical Practice
We present a 63-year-old woman with chronic hepatitis B. The patient has a history of cirrhosis due to chronic hepatitis B and is under treatment with Tenofovir disoproxil fumarate.
Milad Khodabakhshi, Behshad Pazooki
doaj   +1 more source

Modelling the 5‐Year Impact of Twice‐Yearly Injectable Lenacapavir for HIV Pre‐Exposure Prophylaxis in the United States

Journal of the International AIDS Society, Volume 29, Issue 8, August 2026.
Abstract Introduction The impact of pre‐exposure prophylaxis (PrEP) on the US HIV‐1 epidemic has not been fully maximized, potentially due to challenges in uptake, coverage, adherence and consistent use. Following the FDA (Food and Drug Adminstration) approval of twice‐yearly lenacapavir, epidemiological projections are needed to understand the ...
Mia Moore, Serin Lee, Laura Matrajt, Sarah E. Stansfield, Li Tao, Juan Yang, Dylan Mezzio, James Jarrett, JeanPierre Coaquira Castro, Alice Hsiao, Woodie Zachry, Dobromir Dimitrov   +11 more
wiley   +1 more source